drugset / Trial / NCT00768859
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the activity of the combination of paclitaxel, trastuzumab and carboplatin as neo-adjuvant treatment in patients with stage II or III HER2 positive breast cancer
Timeline
- Start
- 2008-09
- Primary completion
- 2011-08
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | — |